8-K: Evercore Reports Record Q2 2026 Results

Evercore Inc. announced record-breaking second quarter and first half 2026 financial results, driven by strong performance across its advisory, private funds, and equities businesses.

Summary

• Evercore Inc. reported record net revenues of $990.2 million for the second quarter of 2026, a 19% increase year-over-year, and $2.4 billion for the first half of 2026, a 56% increase.
• Adjusted net revenues also reached record highs of $999.5 million for Q2 2026 and $2.4 billion for the first half of 2026.
• Operating income on a U.S. GAAP basis was $146.6 million for Q2 2026, while adjusted operating income was $189.7 million.
• Diluted earnings per share (EPS) were $2.32 on a U.S. GAAP basis and $2.91 on an adjusted basis for Q2 2026.
• The company's North America Strategic Advisory, Private Funds Group, and Equities businesses achieved record quarterly revenues.
• Underwriting and Wealth Management businesses also reported their best quarters on record.
• Evercore advised on significant transactions including Arcosa's $8.5 billion sale and Iridium Communications' $8.0 billion sale.
• The company declared a quarterly dividend of $0.89 per share and returned $822.9 million to shareholders in the first six months of 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with record revenues and significant growth across multiple business lines, indicating robust performance and market position.

Positives

• Record second quarter and first half net revenues of $990.2 million and $2.4 billion, respectively.
• Significant year-over-year revenue growth: 19% for Q2 and 56% for the first half.
• Strong performance in key business segments: North America Strategic Advisory, Private Funds Group, and Equities all achieved record quarterly revenues.
• Underwriting and Wealth Management businesses also reported their best quarters on record.
• Successful advisory on major transactions, including Arcosa's $8.5 billion sale and Iridium Communications' $8.0 billion sale.
• Active role as bookrunner in notable underwriting transactions, including the largest biotechnology IPO of all time (Parabilis Medicines $771 million IPO).
• Private Funds Group ranked #1 in PEI's 2025 Placement Agent Ranking.
• Increased Assets Under Management by 12% to $16.2 billion as of June 30, 2026.
• Returned $822.9 million to shareholders through dividends and share repurchases in the first six months of 2026.
• Increased headcount of Senior Managing Directors in Investment Banking to 188 as of June 30, 2026, with seven additional commitments.

Negatives

• U.S. GAAP Net Income Attributable to Evercore Inc. decreased slightly to $95.3 million in Q2 2026 from $97.2 million in Q2 2025.
• U.S. GAAP Diluted Earnings Per Share decreased to $2.32 in Q2 2026 from $2.36 in Q2 2025.
• Non-compensation costs increased by 34% year-over-year in Q2 2026, impacting the non-compensation ratio.
• Special Charges, Including Business Realignment Costs of $21.3 million were recognized in Q2 and year-to-date 2026 for estimated non-U.S. employment taxes.

Risks

• The filing references 'Risk Factors' discussed in Evercore's Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent filings, indicating potential ongoing risks.
• The company notes that financial results can fluctuate significantly due to the timing and amount of transaction fees earned, and other factors, meaning quarterly results may not be representative of longer-term performance.

Future Outlook

The company's leadership expresses confidence in long-term value creation through continued investment in the business and a focus on client engagement, underscoring the firm's competitive strength and breadth.

Management Comments

• "We saw broad-based strength across nearly every business this quarter, reflecting strong client engagement and the benefits of our long-term strategy. We continue to invest in our business and remain focused on creating long-term value for our shareholders."
• "We delivered record second quarter revenues, capping off the strongest first half in our history. These results underscore the greater breadth and competitive strength of our Firm."

Industry Context

StockSavvy.ai notes that Evercore's record results in Q2 2026, particularly in advisory and private funds, align with a strong M&A and private capital markets environment, though increased competition and regulatory scrutiny remain industry-wide considerations.

Comparison to Industry Standards

• Evercore's Private Funds Group ranked #1 in Private Equity International's (PEI) 2025 Placement Agent Ranking, indicating a leading position in capital raising for private equity funds.
• The firm's advisory on major transactions like Arcosa's $8.5 billion sale and Iridium Communications' $8.0 billion sale demonstrates its capability to handle large-scale, complex deals, which is a benchmark for top-tier advisory firms.
• Serving as a lead bookrunner on the Parabilis Medicines $771 million IPO, the largest biotechnology IPO of all time, highlights Evercore's significant presence in the equity capital markets, competing with larger bulge bracket banks.

Legal Proceedings

• Special Charges, Including Business Realignment Costs reflect an estimated loss provision for non-U.S. employment taxes for prior periods. The Company will continue to review its tax position relating to this matter and will adjust this estimate as appropriate in future periods.

Stakeholder Impact

• Shareholders: Benefit from a declared quarterly dividend of $0.89 per share and $822.9 million returned through dividends and repurchases in H1 2026, alongside strong financial performance.
• Employees: Benefit from increased investment in the business and potential for higher incentive compensation, as reflected in increased compensation expenses and the hiring of new Senior Managing Directors.
• Clients: Continue to receive advisory services on significant transactions, with the firm highlighting its role in major deals.
• Investors: Provided with detailed financial results and management commentary, including non-GAAP measures for performance evaluation.

Next Steps

• Continue to invest in the business.
• Focus on creating long-term value for shareholders.
• The company will continue to review its tax position relating to non-U.S. employment taxes and adjust estimates as appropriate.

Key Dates

Recommendation

While the results are strong and indicate record performance, the slight decrease in U.S. GAAP net income and EPS compared to the prior year, coupled with increased non-compensation costs and a provision for prior period employment taxes, warrants a cautious 'hold' rating. The company's forward-looking statements are positive but general, and the reliance on adjusted figures for headline growth requires careful consideration.

Keywords

Investment Banking, Mergers and Acquisitions, Strategic Advisory, Underwriting, Private Funds, Wealth Management, Equity Research, Capital Markets